Author

Nikolai Petrovsky

Professor of Medicine, Flinders University - Cited by 29,535 - Vaccines

Biography

Nikolai Petrovsky  is currently working as a Professor in the Department of Medicine. His research interests includes Medicine. He is serving as an editorial member and reviewer of several international reputed journals. He has successfully completed his Administrative responsibilities. He has authored of many research articles/books related to Medicine.
Title
Cited by
Year
An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2
J Van Helden, CD Butler, G Achaz, B Canard, D Casane, JM Claverie, ...The Lancet 398 (10309), 1402-1404, 2021202
26
2021
Safety and immunogenicity of SpikoGen®, an Advax-CpG55. 2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and …
P Tabarsi, N Anjidani, R Shahpari, M Mardani, A Sabzvari, B Yazdani, ...Clinical Microbiology and Infection 28 (9), 1263-1271, 202
22
2022
An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission
K Tabynov, N Turebekov, M Babayeva, G Fomin, T Yerubayev, ...npj Vaccines 7 (1), 24, 2022202
14
2022
Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55. 2 adjuvant provides single dose protection against SARS-CoV-2 infection in …
L Li, Y Honda-Okubo, J Baldwin, R Bowen, H Bielefeldt-Ohmann, ...Vaccine 40 (23), 3182-3192, 2022202
13
2022
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
A Kaur, J Baldwin, D Brar, DB Salunke, N PetrovskyCurrent Opinion in Chemical Biology 70, 102172, 2022202
13
2022
Artificial intelligence in vaccine and drug design
S Thomas, A Abraham, J Baldwin, S Piplani, N PetrovskyVaccine Design: Methods and Protocols, Volume 1. Vaccines for Human Diseases …, 2022202
12
2022
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo …
P Tabarsi, N Anjidani, R Shahpari, K Roshanzamir, N Fallah, G Andre, ...Immunology 167 (3), 340-353, 2022202
10
2022
Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. 2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized …
P Tabarsi, N Anjidani, R Shahpari, M Mardani, A Sabzvari, B Yazdani, ...Clinical Microbiology and Infection 29 (2), 215-220, 2023202
8
2023
A Spike protein-based subunit SARS-CoV-2 vaccine for pets: safety, immunogenicity, and protective efficacy in juvenile cats
K Tabynov, M Orynbassar, L Yelchibayeva, N Turebekov, T Yerubayev, ...Frontiers in Veterinary Science 9, 1597, 2022202
8
2022
Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
S Piplani, PK Singh, DA Winkler, N PetrovskyMolecular biomedicine 2, 1-12, 2021202
8
2021
Combined delivery of TLR2 and TLR7 agonists by Nanostructured lipid carriers induces potent vaccine adjuvant activity in mice
Combined delivery of TLR2 and TLR agonists by Nanostructured lipid carriers induces potent vaccine adjuvant activity in miceA Kaur, R Kanwar, D Kaushik, IG Sakala, Y Honda-Okubo, N Petrovsky, ...International Journal of Pharmaceutics 613, 12138, 2022202
7
2022
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies
S Piplani, P Singh, N Petrovsky, DA WinklerFrontiers in Molecular Biosciences 9, 781039, 2022202
6
2022
Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates
H Li, MA Monslow, DC Freed, D Chang, F Li, M Gindy, D Wang, K Vora, ...Vaccine 39 (1), 7446-746, 2021202
5
2021
Potential COVID-19 Therapies from computational repurposing of drugs and natural products against the SARS-CoV-2 helicase
S Piplani, P Singh, DA Winkler, N PetrovskyInternational Journal of Molecular Sciences 23 (1), 770, 2022202
4
2022
Stereoisomeric Pam 2 CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants
A Kaur, S Piplani, D Kaushik, J Fung, IG Sakala, Y Honda-Okubo, ...RSC Medicinal Chemistry 13 (5), 622-637, 2022202
4
2022
Co-Administration of adjuvanted recombinant ov-103 and ov-Ral-2 vaccines confer protection against natural challenge in a bovine onchocerca ochengi infection model of human …
L Luu, GS Bah, NH Okah-Nnane, CS Hartley, AF Glover, TR Walsh, ...Vaccines 10 (6), 861, 2022202
4
2022
An advax-adjuvanted inactivated cell-culture derived Japanese encephalitis vaccine induces broadly neutralising anti-flavivirus antibodies, robust cellular immunity and …
T Komiya, Y Honda-Okubo, J Baldwin, N PetrovskyVaccines 9 (11), 1235, 2021202
4
2021
A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model
L Jelínková, Y Flores-Garcia, S Shapiro, BT Roberts, N Petrovsky, ...npj Vaccines 7 (1), 4, 2022202
3
2022
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the …
S Perez-Lloret, N Petrovsky, A Alami, JAG Crispo, D Mattison, ...medRxiv, 2021.09. 28.21264245, 2021202
3
2021
Evaluation of a novel adjuvanted vaccine for ultrashort regimen therapy of artemisia pollen-induced allergic bronchial asthma in a mouse model
K Tabynov, M Babayeva, T Nurpeisov, G Fomin, T Nurpeisov, ...Frontiers in immunology 1, 828690, 2022202
3
2022

Referred From: https://scholar.google.com/citations?hl=en&user=S04VpOsAAAAJ

Cited by
Citations 29535
h-index 64
i10-index 183
Recommended Journals
Open Access Journals